Advertise
NEWSLETTER
Function, Google partner to...
Immorta Bio develops AI-des...
Phase 1b data show Rubedo L...
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Function, Google partner to...
Immorta Bio develops AI-des...
Phase 1b data show Rubedo L...
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Rejuvenation therapies

The use of TORC1 inhibitors to improve immune function in the elderly

How do we show in humans that a drug targets aging?

Project 21 & Aubrey de Grey

The divide-and-conquer nature of rejuvenation can be an asset, not a challenge

Aubrey de Grey, Founder and CEO, SENS Foundation.

Geroprotectors: time to change the way we treat older people?

Removal of senescent cells to extend healthspan & lifespan

Reason

The undeveloped hinterland of rejuvenation

Group discussion with various Day 2 speakers

Biotech AgeX Therapeutics reported financial and commercialises its stem cell lines, but continues to borrow from stakeholder Juvenescence.

Supercentenarians – reprogramming cells

From Longevity signatures to Longevity interventions

Joao Pedro de Maghlaes

Anti-aging biotech: past, present and future

Rejuvenated stem cells to reverse aging

‘Rejuvenation therapies’ Ask Me Anything

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed